IP Library Granted Patent US 12,098,146
Granted Patent B2
US 12,098,146 · App. 16/751,803 · Granted Sep 24, 2024

Compounds and uses thereof

Inventors: Iwona Wrona (Sharon, MA); Kerem Ozboya (Cambridge, MA); Matthew Lucas (Lexington, MA); Bhaumik Pandya (Bedford, MA); Bertrand Le Bourdonnec (Northborough, MA)
Assignee: JANSSEN PHARMACEUTICA NV
C07D413/14A61P35/04C07D401/06C07D401/12C07D403/12C07D413/04C07D417/14A61K31/495
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,146
App. No.
16/751,803
Granted
Sep 24, 2024
Kind
B2
Abstract

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

Claims (40)

1. A compound of formula (III-D-1):

wherein:

o is 2;

C 1 and C 2 optionally combine to form a bond;

each of R 1 , R 2 , and R 6 is, independently, H or optionally substituted C 1-6 alkyl;

R 3 is halo;

R 4 is H, OR 6 , optionally substituted C 1-6 alkyl, or halo;

L 1 is optionally substituted C 5-10 heteroaryl or —C(O)—X 5 —;

X 5 is NH, O, or optionally substituted C 1-6 alkyl; and

L 2 is O;

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1 , and a pharmaceutically acceptable excipient.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R 2 is H.

6. The compound of claim 1 , wherein R 4 is H.

7. The compound of claim 1 , wherein R 1 is methyl.

8. The compound of claim 1 , wherein L 1 is

9. The compound of claim 8 , wherein R 4 is H.

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 3 , wherein the compound is:

11. The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 3 , wherein the compound is

17. The compound of claim 3 , wherein the compound is

18. The compound of claim 3 , wherein the compound is

19. The compound of claim 3 , wherein the compound is

20. The compound of claim 3 , wherein the compound is

21. The compound of claim 3 , wherein the compound is

22. The compound of claim 3 , wherein the compound is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: YUMANITY THERAPEUTICS, INC.; YUMANITY, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 062148/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: WRONA, IWONA; OZBOYA, KEREM; LUCAS, MATTHEW; PANDYA, BHAUMIK; LE BOURDONNEC, BERTRAND
To: YUMANITY THERAPEUTICS, INC.
Reel/Frame 051946/0944 →
Continuity (4)
Provisional Application 62934900 · Nov 13, 2019
Provisional Application 62822353 · Mar 22, 2019
Provisional Application 62796411 · Jan 24, 2019
Related Publication 20210139471A1 · May 13, 2021